1.Efficacy and safety of human chorionic gonadotropin combined with human menopausal gonadotropin and a gonadotropin-releasing hormone pump for male adolescents with congenital hypogonadotropic hypogonadism.
Ying LIU ; Xiao-Ya REN ; Ya-Guang PENG ; Shao-Ke CHEN ; Xin-Ran CHENG ; Miao QIN ; Xiao-Ling WANG ; Yan-Ning SONG ; Li-Jun FAN ; Chun-Xiu GONG
Chinese Medical Journal 2021;134(10):1152-1159
BACKGROUND:
Compared to adult studies, studies which involve the treatment of pediatric congenital hypogonadotropic hypogonadism (CHH) are limited and no universal treatment regimen is available. The aim of this study was to evaluate the feasibility of human chorionic gonadotropin (hCG)/human menopausal gonadotropin (hMG) therapy for treating male adolescents with CHH.
METHODS:
Male adolescent CHH patients were treated with hCG/hMG (n = 20) or a gonadotropin-releasing hormone (GnRH) pump (n = 21). The treatment was divided into a study phase (0-3 months) and a follow-up phase (3-12 months). The testicular volume (TV), penile length (PL), penis diameter (PD), and sex hormone levels were compared between the two groups. The TV and other indicators between the groups were analyzed using a t-test (equal variance) or a rank sum test (unequal variance).
RESULTS:
Before treatment, there was no statistical difference between the two groups in terms of the biochemistry, hormones, and other demographic indicators. After 3 months of treatment, the TV of the hCG/hMG and GnRH groups increased to 5.1 ± 2.3 mL and 4.1 ± 1.8 mL, respectively; however, the difference was not statistically significant (P > 0.05, t = 1.394). The PL reached 6.9 ± 1.8 cm and 5.1 ± 1.6 cm (P < 0.05, t = 3.083), the PD reached 2.4 ± 0.5 cm and 2.0 ± 0.6 cm (P < 0.05, t = 2.224), respectively, in the two groups. At the end of 6 months of treatment, biomarkers were in normal range in the two groups. Compared with the GnRH group, the testosterone (T) level and growth of PL and PD were significantly greater in the hCG/hMG group (all P < 0.05). While the TV of both groups increased, the difference was not statistically significant (P > 0.05, t = 0.314). After 9 to 12 months of treatment, the T level was higher in the hCG/hMG group. Other parameters did not exhibit a statistical difference.
CONCLUSIONS:
The hCG/hMG regimen is feasible and effective for treating male adolescents with CHH. The initial 3 months of treatment may be a window to optimally observe the strongest effects of therapy. Furthermore, results from the extended time-period showed positive outcomes at the 1-year mark; however, the long-term effectiveness, strengths, and weaknesses of the hCG/hMG regimen require further research.
TRIAL REGISTRATION
ClinicalTrials.gov, NCT02880280; https://clinicaltrials.gov/ct2/show/NCT02880280.
Adolescent
;
Adult
;
Child
;
Chorionic Gonadotropin/therapeutic use*
;
Gonadotropin-Releasing Hormone
;
Humans
;
Hypogonadism/drug therapy*
;
Male
;
Menotropins/therapeutic use*
;
Spermatogenesis
;
Testosterone
2.Trigger effect of hMG and hCG in the treatment of unexplainable non-obstructive azoospermia.
Hao-Rui HU ; Hong-Chuan NIE ; Wei-Min YANG ; Yuan SUN ; Hui HUANG ; Fang-Gang XIE
National Journal of Andrology 2017;23(9):813-816
Objective:
To investigate whether the trigger effect of human menopausal gonadotropins (hMG) and human chorionic gonadotropins (hCG) attributes to the treatment of unexplainable non-obstructive azoospermia (NOA).
METHODS:
We retrospectively analyzed the clinical data about 282 cases of unexplainable NOA treated in the Maternity and Child Health Hospital of Guizhou Province from January 2010 to May 2017. All the patients underwent trigger treatment by intramuscular injection of hMG at 75 IU 3 times a week for 2 weeks, followed by hCG at 2 000 IU twice a week for another 2 weeks, and meanwhile took vitamin E, Levocarnitine and Tamoxifen as an adjunctive therapy. The treatment lasted 3-12 months.
RESULTS:
Fifty-eight of the 255 patients that completed the treatment were found with sperm in the semen after treatment, all with severe oligoasthenospermia. Forty-seven of the 58 cases received assisted reproductive technology (ART), of which 18 achieved clinical pregnancy. Semen centrifugation revealed no sperm in the other cases, of which 6 were found with epididymal sperm at epididymal and testicular biopsy after treatment and 3 of them achieved clinical pregnancy after ART. Sperm was found in the semen or at epididymal or testicular biopsy in 64 of the patients after treatment, with an effectiveness rate of 25.1%.
CONCLUSIONS
Trigger treatment by injection of hMG and hCG combined with adjunctive oral medication has a certain effect on unexplainable NOA.
Azoospermia
;
drug therapy
;
Chorionic Gonadotropin
;
therapeutic use
;
Drug Administration Schedule
;
Epididymis
;
Female
;
Fertility Agents, Male
;
therapeutic use
;
Humans
;
Injections, Intramuscular
;
Male
;
Menotropins
;
therapeutic use
;
Pregnancy
;
Pregnancy Rate
;
Reproductive Techniques, Assisted
;
Retrospective Studies
;
Sperm Retrieval
;
statistics & numerical data
;
Spermatozoa
;
Testis
3.Modified super-long down-regulation protocol improved the outcome of in vitro fertilization-embryo transfer in infertile patients.
Fei GONG ; Yi TANG ; Hong ZHANG ; Guangxiu LU
Journal of Central South University(Medical Sciences) 2009;34(3):185-189
OBJECTIVE:
To investigate the outcome of in vitro fertilization and embryo transfer (IVF-ET) in special infertile patients following modified super-long down-regulation protocol combined with human menopausal gonadotropin (HMG) stimulation.
METHODS:
Ninety-nine special patients (42 with endometriosis, 35 with PCOS, and 22 with insufficient down-regulation) who underwent modified super-long down-regulation protocol in 2008 were retrospectively analyzed. Gonadotropin releasing hormone analogues (GnRHa, 1.5 mg) was injected intramuscularly in mid-luteal phase twice and HMG was started 25 days later after the second GnRHa injection. Conventional IVF-ET was performed as routine procedure. The clinical outcomes were compared with those of 122 similar patients in the same period.
RESULTS:
After modified super-long down-regulation, (1) in endometriosis patients, the average gonadotropin (Gn) used was (32.33 +/- 15.11) ampoules, duration of medication was (10.57 +/- 1.88) days, the progesterone (P) level on hCG day was (0.78 +/- 0.44) microg/L, and the clinical pregnancy rate (CPR) was 73.8%; (2) in PCOS patients, the average Gn used was (28.57 +/- 12.07) ampoules, the duration of medication was (11.71 +/- 2.07) days, the P level at hCG day was (0.65 +/- 0.39) microg/L, and the clinical pregnancy rate was 65.7%; (3) in insufficient down-regulation patients, the average Gn used was (26.22 +/- 12.07) ampoules, the duration of medication was (10.01 +/- 1.77) days, the P level at hCG day was (0.71 +/- 0.50) microg/L, and the clinical pregnancy rate was 72.7%. Compared with patients using regular down-regulation protocol, the clinical pregnancy rate was improved significantly and the cost decreased obviously. The clinical pregnancy rate significantly improved compared with that of routine long down-regulation groups.
CONCLUSION
Revised super-long protocol plus HMG is a cost-effective controlled ovary hyperstimulation (COH) regimen for infertile patients with endometriosis, PCOS and insufficient down-regulation.
Adult
;
Embryo Transfer
;
methods
;
Endometriosis
;
complications
;
Female
;
Fertility Agents, Female
;
therapeutic use
;
Fertilization in Vitro
;
methods
;
Gonadotropin-Releasing Hormone
;
agonists
;
therapeutic use
;
Humans
;
Infertility, Female
;
etiology
;
therapy
;
Menotropins
;
therapeutic use
;
Ovulation Induction
;
economics
;
methods
;
Polycystic Ovary Syndrome
;
complications
;
Pregnancy
;
Retrospective Studies
;
Treatment Outcome